Selected research
Industry Research
Generic and Biosimilar Pharmaceuticals Industry Research Report 2026
Market perspective
The global Generic and Biosimilar Pharmaceuticals market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Generic and Biosimilar Pharmaceuticals market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Generic and Biosimilar Pharmaceuticals market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Generic and Biosimilar Pharmaceuticals market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Generic and Biosimilar Pharmaceuticals include Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Amgen, AbbVie and Sanofi-Aventis, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Generic and Biosimilar Pharmaceuticals market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Generic and Biosimilar Pharmaceuticals.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Generic and Biosimilar Pharmaceuticals Market by Company
Johnson & Johnson
Novartis
Merck
Roche
Eli Lilly
Pfizer
Amgen
AbbVie
Sanofi-Aventis
Novo Nordisk
Innovent
Gelgen
Ganlee
Dong Bao
CP Guojian
Changchun High Tech
Biotech
3sbio
Generic and Biosimilar Pharmaceuticals Segment by Type
Erythropoietin
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Other
Generic and Biosimilar Pharmaceuticals Segment by Application
Tumor
Hemophilia
Cardiovascular
Diabetes
Other
Generic and Biosimilar Pharmaceuticals Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic and Biosimilar Pharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Generic and Biosimilar Pharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic and Biosimilar Pharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Generic and Biosimilar Pharmaceuticals companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Erythropoietin
- Monoclonal Antibodies
- Interferon
- Insulin
- Vaccines
- Other
Applications
- Tumor
- Hemophilia
- Cardiovascular
- Diabetes
- Other
Companies covered
- Johnson & Johnson
- Novartis
- Merck
- Roche
- Eli Lilly
- Pfizer
- Amgen
- AbbVie
- Sanofi-Aventis
- Novo Nordisk
- Innovent
- Gelgen
- Ganlee
- Dong Bao
- CP Guojian
- Changchun High Tech
- Biotech
- 3sbio
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Generic and Biosimilar Pharmaceuticals by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Erythropoietin
- 2.2.3 Monoclonal Antibodies
- 2.2.4 Interferon
- 2.2.5 Insulin
- 2.2.6 Vaccines
- 2.2.7 Other
- 2.3 Generic and Biosimilar Pharmaceuticals by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Tumor
- 2.3.3 Hemophilia
- 2.3.4 Cardiovascular
- 2.3.5 Diabetes
- 2.3.6 Other
- 2.4 Assumptions and Limitations
3 Generic and Biosimilar Pharmaceuticals Breakdown Data by Type
- 3.1 Global Generic and Biosimilar Pharmaceuticals Historic Market Size by Type (2021-2026)
- 3.2 Global Generic and Biosimilar Pharmaceuticals Forecasted Market Size by Type (2027-2032)
4 Generic and Biosimilar Pharmaceuticals Breakdown Data by Application
- 4.1 Global Generic and Biosimilar Pharmaceuticals Historic Market Size by Application (2021-2026)
- 4.2 Global Generic and Biosimilar Pharmaceuticals Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Generic and Biosimilar Pharmaceuticals Market Perspective (2021-2032)
- 5.2 Global Generic and Biosimilar Pharmaceuticals Growth Trends by Region
- 5.2.1 Global Generic and Biosimilar Pharmaceuticals Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Generic and Biosimilar Pharmaceuticals Historic Market Size by Region (2021-2026)
- 5.2.3 Generic and Biosimilar Pharmaceuticals Forecasted Market Size by Region (2027-2032)
- 5.3 Generic and Biosimilar Pharmaceuticals Market Dynamics
- 5.3.1 Generic and Biosimilar Pharmaceuticals Industry Trends
- 5.3.2 Generic and Biosimilar Pharmaceuticals Market Drivers
- 5.3.3 Generic and Biosimilar Pharmaceuticals Market Challenges
- 5.3.4 Generic and Biosimilar Pharmaceuticals Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Generic and Biosimilar Pharmaceuticals Players by Revenue
- 6.1.1 Global Top Generic and Biosimilar Pharmaceuticals Players by Revenue (2021-2026)
- 6.1.2 Global Generic and Biosimilar Pharmaceuticals Revenue Market Share by Players (2021-2026)
- 6.2 Global Generic and Biosimilar Pharmaceuticals Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Generic and Biosimilar Pharmaceuticals Head Office and Area Served
- 6.4 Global Generic and Biosimilar Pharmaceuticals Players, Product Type & Application
- 6.5 Global Generic and Biosimilar Pharmaceuticals Manufacturers Established Date
- 6.6 Global Generic and Biosimilar Pharmaceuticals Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Generic and Biosimilar Pharmaceuticals Market Size (2021-2032)
- 7.2 North America Generic and Biosimilar Pharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Generic and Biosimilar Pharmaceuticals Market Size by Country (2021-2026)
- 7.4 North America Generic and Biosimilar Pharmaceuticals Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Generic and Biosimilar Pharmaceuticals Market Size (2021-2032)
- 8.2 Europe Generic and Biosimilar Pharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Generic and Biosimilar Pharmaceuticals Market Size by Country (2021-2026)
- 8.4 Europe Generic and Biosimilar Pharmaceuticals Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size (2021-2032)
- 9.2 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Generic and Biosimilar Pharmaceuticals Market Size (2021-2032)
- 10.2 South America Generic and Biosimilar Pharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Generic and Biosimilar Pharmaceuticals Market Size by Country (2021-2026)
- 10.4 South America Generic and Biosimilar Pharmaceuticals Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size (2021-2032)
- 11.2 Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Johnson & Johnson
- 12.1.1 Johnson & Johnson Company Information
- 12.1.2 Johnson & Johnson Business Overview
- 12.1.3 Johnson & Johnson Revenue in Generic and Biosimilar Pharmaceuticals Business (2021-2026)
- 12.1.4 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Product Portfolio
- 12.1.5 Johnson & Johnson Recent Developments
- 12.2 Novartis
- 12.2.1 Novartis Company Information
- 12.2.2 Novartis Business Overview
- 12.2.3 Novartis Revenue in Generic and Biosimilar Pharmaceuticals Business (2021-2026)
- 12.2.4 Novartis Generic and Biosimilar Pharmaceuticals Product Portfolio
- 12.2.5 Novartis Recent Developments
- 12.3 Merck
- 12.3.1 Merck Company Information
- 12.3.2 Merck Business Overview
- 12.3.3 Merck Revenue in Generic and Biosimilar Pharmaceuticals Business (2021-2026)
- 12.3.4 Merck Generic and Biosimilar Pharmaceuticals Product Portfolio
- 12.3.5 Merck Recent Developments
- 12.4 Roche
- 12.4.1 Roche Company Information
- 12.4.2 Roche Business Overview
- 12.4.3 Roche Revenue in Generic and Biosimilar Pharmaceuticals Business (2021-2026)
- 12.4.4 Roche Generic and Biosimilar Pharmaceuticals Product Portfolio
- 12.4.5 Roche Recent Developments
- 12.5 Eli Lilly
- 12.5.1 Eli Lilly Company Information
- 12.5.2 Eli Lilly Business Overview
- 12.5.3 Eli Lilly Revenue in Generic and Biosimilar Pharmaceuticals Business (2021-2026)
- 12.5.4 Eli Lilly Generic and Biosimilar Pharmaceuticals Product Portfolio
- 12.5.5 Eli Lilly Recent Developments
- 12.6 Pfizer
- 12.6.1 Pfizer Company Information
- 12.6.2 Pfizer Business Overview
- 12.6.3 Pfizer Revenue in Generic and Biosimilar Pharmaceuticals Business (2021-2026)
- 12.6.4 Pfizer Generic and Biosimilar Pharmaceuticals Product Portfolio
- 12.6.5 Pfizer Recent Developments
- 12.7 Amgen
- 12.7.1 Amgen Company Information
- 12.7.2 Amgen Business Overview
- 12.7.3 Amgen Revenue in Generic and Biosimilar Pharmaceuticals Business (2021-2026)
- 12.7.4 Amgen Generic and Biosimilar Pharmaceuticals Product Portfolio
- 12.7.5 Amgen Recent Developments
- 12.8 AbbVie
- 12.8.1 AbbVie Company Information
- 12.8.2 AbbVie Business Overview
- 12.8.3 AbbVie Revenue in Generic and Biosimilar Pharmaceuticals Business (2021-2026)
- 12.8.4 AbbVie Generic and Biosimilar Pharmaceuticals Product Portfolio
- 12.8.5 AbbVie Recent Developments
- 12.9 Sanofi-Aventis
- 12.9.1 Sanofi-Aventis Company Information
- 12.9.2 Sanofi-Aventis Business Overview
- 12.9.3 Sanofi-Aventis Revenue in Generic and Biosimilar Pharmaceuticals Business (2021-2026)
- 12.9.4 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Product Portfolio
- 12.9.5 Sanofi-Aventis Recent Developments
- 12.10 Novo Nordisk
- 12.10.1 Novo Nordisk Company Information
- 12.10.2 Novo Nordisk Business Overview
- 12.10.3 Novo Nordisk Revenue in Generic and Biosimilar Pharmaceuticals Business (2021-2026)
- 12.10.4 Novo Nordisk Generic and Biosimilar Pharmaceuticals Product Portfolio
- 12.10.5 Novo Nordisk Recent Developments
- 12.11 Innovent
- 12.11.1 Innovent Company Information
- 12.11.2 Innovent Business Overview
- 12.11.3 Innovent Revenue in Generic and Biosimilar Pharmaceuticals Business (2021-2026)
- 12.11.4 Innovent Generic and Biosimilar Pharmaceuticals Product Portfolio
- 12.11.5 Innovent Recent Developments
- 12.12 Gelgen
- 12.12.1 Gelgen Company Information
- 12.12.2 Gelgen Business Overview
- 12.12.3 Gelgen Revenue in Generic and Biosimilar Pharmaceuticals Business (2021-2026)
- 12.12.4 Gelgen Generic and Biosimilar Pharmaceuticals Product Portfolio
- 12.12.5 Gelgen Recent Developments
- 12.13 Ganlee
- 12.13.1 Ganlee Company Information
- 12.13.2 Ganlee Business Overview
- 12.13.3 Ganlee Revenue in Generic and Biosimilar Pharmaceuticals Business (2021-2026)
- 12.13.4 Ganlee Generic and Biosimilar Pharmaceuticals Product Portfolio
- 12.13.5 Ganlee Recent Developments
- 12.14 Dong Bao
- 12.14.1 Dong Bao Company Information
- 12.14.2 Dong Bao Business Overview
- 12.14.3 Dong Bao Revenue in Generic and Biosimilar Pharmaceuticals Business (2021-2026)
- 12.14.4 Dong Bao Generic and Biosimilar Pharmaceuticals Product Portfolio
- 12.14.5 Dong Bao Recent Developments
- 12.15 CP Guojian
- 12.15.1 CP Guojian Company Information
- 12.15.2 CP Guojian Business Overview
- 12.15.3 CP Guojian Revenue in Generic and Biosimilar Pharmaceuticals Business (2021-2026)
- 12.15.4 CP Guojian Generic and Biosimilar Pharmaceuticals Product Portfolio
- 12.15.5 CP Guojian Recent Developments
- 12.16 Changchun High Tech
- 12.16.1 Changchun High Tech Company Information
- 12.16.2 Changchun High Tech Business Overview
- 12.16.3 Changchun High Tech Revenue in Generic and Biosimilar Pharmaceuticals Business (2021-2026)
- 12.16.4 Changchun High Tech Generic and Biosimilar Pharmaceuticals Product Portfolio
- 12.16.5 Changchun High Tech Recent Developments
- 12.17 Biotech
- 12.17.1 Biotech Company Information
- 12.17.2 Biotech Business Overview
- 12.17.3 Biotech Revenue in Generic and Biosimilar Pharmaceuticals Business (2021-2026)
- 12.17.4 Biotech Generic and Biosimilar Pharmaceuticals Product Portfolio
- 12.17.5 Biotech Recent Developments
- 12.18 3sbio
- 12.18.1 3sbio Company Information
- 12.18.2 3sbio Business Overview
- 12.18.3 3sbio Revenue in Generic and Biosimilar Pharmaceuticals Business (2021-2026)
- 12.18.4 3sbio Generic and Biosimilar Pharmaceuticals Product Portfolio
- 12.18.5 3sbio Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst